CRL
Chaseville Road Labs
Molecular · PCR · Diagnostics
HomeTest MenuRespiratory
Rapid Triage · 5-Target Respiratory Panel

Five Viruses. One Swab. Results in 24 Hours.

The five questions you actually ask in respiratory virus season — SARS-CoV-2, Flu A, Flu B, RSV A, RSV B — answered in one run.

Clinical use
The Outpatient Respiratory Bench
0
High-Impact Viruses
0
NP Swab
0
Hour TAT for results
0
Days a Year
The clinical problem
Symptomatic triage shouldn't require five separate tests.

Outpatient respiratory season is a stream of patients who all look the same at the front desk: cough, fever, congestion. The clinical question is binary per pathogen — antiviral, isolation, return to work — but the differential is five-deep.

One nasopharyngeal swab, one multiplex PCR run, all five high-impact respiratory viruses resolved in 24–48 hours. No stacking of rapid antigen, send-out flu PCR, and a separate RSV order.

By the Numbers

The clinical weight behind this panel.

Industry statistics from public-health bodies and peer-reviewed literature — context for why this testing matters.

4 viruses
drive the majority of seasonal respiratory illness: Flu A/B, RSV, SARS-CoV-2
Source · CDC ILI Surveillance
>90%
sensitivity of multiplex PCR for influenza vs. rapid antigen ~50–70%
Source · IDSA
48 hrs
window where oseltamivir most reduces flu severity

Same-day PCR keeps that window open.

Source · CDC
$10B+
annual U.S. economic burden of seasonal influenza
Source · CDC

Figures reflect publicly reported epidemiology and clinical literature for context only. They are not performance claims for the Chaseville Labs assay. See individual citations from the U.S. Centers for Disease Control and Prevention, World Health Organization, National Institutes of Health, and peer-reviewed journals.

What This Panel Diagnoses

Conditions, syndromes & infections covered.

The clinical scenarios where this panel is the right call — built around the differential your providers are actually working through.

Seasonal Respiratory Viruses

3
COVID-19 (SARS-CoV-2)

Confirmatory PCR for symptomatic patients during respiratory virus season.

Clinical Impact ·Drives Paxlovid (nirmatrelvir/ritonavir) eligibility within the 5-day treatment window, return-to-work decisions, and exposure tracing.
Influenza A & B

The classic flu — fever, body aches, cough, fatigue, often severe in elderly and pediatric patients.

Clinical Impact ·Confirmed detection drives oseltamivir (Tamiflu) or baloxavir prescribing within the 48-hour treatment window — every hour matters.
RSV Bronchiolitis & Pneumonia (RSV A, RSV B)

Leading cause of hospitalization in infants and a major driver of pneumonia in elderly adults.

Clinical Impact ·Subtyping supports pediatric and senior-care triage; positive RSV in high-risk infants may qualify for nirsevimab or palivizumab follow-up.

Triage Decisions

2
Undifferentiated cough, fever, congestion

The patient at the front desk who could have any of five things — resolved in one swab.

Clinical Impact ·Eliminates the rapid-antigen → send-out flu PCR → separate RSV stacking that costs days and copays.
Co-infection screening

Flu + COVID, COVID + RSV, and other dual infections that worsen outcomes.

Clinical Impact ·Single multiplex result captures co-infection in one report — antigen testing one virus at a time misses these.
Complete Target List

5 targets, resolved from a single specimen.

Each organism below is reported individually as Detected, Not Detected, or Inconclusive — grouped here by pathogen class for clinical scanability.

Viral

5 targets
SARS-CoV-2Influenza AInfluenza BRSV ARSV B
Why Molecular

Culture was built for a different century.

Multiplex real-time PCR resolves what culture and rapid antigen miss — fastidious organisms, polymicrobial infections, viruses, and resistance markers — from a single specimen.

Conventional
The Old Way

Culture & rapid antigen

  • 3–5 days
    Patient empirically treated before any answer arrives
  • Misses fastidious & viral organisms
    No growth ≠ no infection
  • Single-organism bias
    Polymicrobial infections under-reported
  • No resistance data
    Susceptibilities arrive a day later, if at all
  • Specimen-quality dependent
    Pre-treated patients culture negative
Multiplex PCR
The CRL Way

Respiratory on Bio-Rad CFX384

  • 24–48 hours
    Most reports back the next clinical day
  • 5 targets, one run
    Bacterial, viral, fungal, and parasitic in a single multiplex
  • Detects what culture can't
    Fastidious organisms, viruses, and polymicrobial infections, all reported individually
  • Validated LDT
    CLIA-certified, internally controlled, per-target Detected / Not Detected reporting
Primary Specimen
Copan E-swab / NP swab
Collection Container
Universal transport medium (UTM/VTM)
Volume
1–3 mL
Storage
2–8°C up to 72 hours
Transport
Pre-paid FedEx Priority Overnight
Stability
Validated per storage condition
Chain of Custody
Barcoded, temperature-logged in transit
Result Format

Per-target results, with clinical context.

Every analyte is reported individually as Detected, Not Detected, or Inconclusive. What a Detected result means clinically depends on which category the target falls into:

Viral
SARS-CoV-2Influenza AInfluenza BRSV ARSV B
If Detected

Rapid differentiation of SARS-CoV-2, influenza A/B, and RSV directs antiviral eligibility (oseltamivir, nirmatrelvir, RSV mAb prophylaxis), isolation, and cohorting decisions in the first visit.

Qualitative multiplex real-time PCR (Bio-Rad CFX384)
Turnaround: 24–48 hours